Skip to main content

Overactive Bladder for Men with Benign Prostatic Hyperplasia

This study is currently active

Northern California Research is conducting a phase 3 clinical research study to evaluate the safety, effectiveness, and tolerability of the study medication Vibegron in Men with Overactive Bladder (OAB) symptoms on Pharmalogical Therapy for Benign Prostatic Hyperplasia (BPH).

Eligibility Criteria:

  • Must be a male, 45 years or older
  • Currently on a stable dose of a BPH treatment, and continue to remain on that treatment throughout the study.
  • Having symptoms of an overactive bladder (OAB)
  • PSA level <4 ng/mL

This study is 30 weeks long and includes 11 office visits. The trial doctor will review other eligibility criteria with you. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided.

Please refer to this study by its identifier (NCT number): NCT03492281

Participate in a Study

Submit the form and a clinical study expert will get in touch with you.

Want to know more about our clinical trials?